Molnupiravir may be the most plentiful option as cases soar, driven by the omicron variant. The federal government dispatched 65,000 treatment courses of Pfizer’s antiviral Paxlovid in its first shipment this week. Merck will deliver “several hundred thousand” treatment courses in the next couple of days, and up to 1 million doses in the next two weeks, said John McGrath, Merck’s senior vice president of external manufacturing and strategy.
FDA authorizes Mercks anti-coronavirus pill, a second at-home treatment option – The Washington Post
